Delivery of gene-expressing fragments using quantum dot

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 7189, Issue , 2009, Pages

  Hoshino, Akiyoshi ^a,b   Manabe, Noriyoshi ^a,c   Hanada, Sanshiro ^a,c   Fujioka, Kouki ^a,d   Yasuhara, Masato ^b   Akihiko, Kondo ^e   Yamamoto, Kenji ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Japan Association for the Advancement of Medical Equipment   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KOBE UNIVERSITY   (Japan)

Author keywords

Gene delivery; Gene therapy; Immune response; Nanoparticle,; Quantum dot; Transfection

Indexed keywords

GENE DELIVERY; GENE THERAPY; IMMUNE RESPONSE; QUANTUM DOT; TRANSFECTION;

AMINES; ANIMAL CELL CULTURE; BIOCHEMISTRY; CELL CULTURE; CUSTOMER SATISFACTION; ENZYME ACTIVITY; FLUORESCENCE; GENE TRANSFER; HEALTH RISKS; IMMUNOLOGY; LIPOSOMES; MAMMALS; NANOCRYSTALS; NANOPARTICLES; NUCLEIC ACIDS; OPTICAL WAVEGUIDES; PHOSPHOLIPIDS; PHYSIOLOGICAL MODELS; PROTEINS;

SEMICONDUCTOR QUANTUM DOTS;

EID: 66749176246     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.808775     Document Type: Conference Paper

References (51)

1. T. R. Flotte, M. L. Brantly, L. T. Spencer, B. J. Byrne, C. T. Spencer, D. J. Baker, and M. Humphries, "Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CBhAAT) gene vector to AAT-deficient adults," Hum Gene Ther,15(1),93-128(2004).
2. M. L. Brantly, L. T. Spencer, M. Humphries, T. J. Conlon, C. T. Spencer, A. Poirier, W. Garlington, D. Baker, S. Song, K. I. Berns, N. Muzyczka, R. O. Snyder, B. J. Byrne, and T. R. Flotte, "Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults," Hum Gene Ther,17(12),1177-1186(2006) .
3. T. R. Flotte, P. L. Zeitlin, T. C. Reynolds, A. E. Heald, P. Pedersen, S. Beck, C. K. Conrad, L. Brass-Ernst, M. Humphries, K. Sullivan, R. Wetzel, G. Taylor, B. J. Carter, and W. B. Guggino, "Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study," Hum Gene Ther,14(11),1079-1088(2003).
4. J. A. Wagner, I. B. Nepomuceno, A. H. Messner, M. L. Moran, E. P. Batson, S. Dimiceli, B. W. Brown, J. K. Desch, A. M. Norbash, C. K. Conrad, W. B. Guggino, T. R. Flotte, J. J. Wine, B. J. Carter, T. C. Reynolds, R. B. Moss, and P. Gardner, "A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies," Hum Gene Ther,13(11),1349-1359(2002).
5. M. A. Kay, C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, V. Arruda, F. Johnson, C. Scallan, E. Skarsgard, A. W. Flake, and K. A. High, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," Nat Genet,24(3),257-261(2000).
6. C. S. Manno, A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, L. B. Couto, D. G. Leonard, F. A. Johnson, A. McClelland, C. Scallan, E. Skarsgard, A. W. Flake, M. A. Kay, K. A. High, and B. Glader, "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B," Blood,101(8),2963-2972(2003).
7. J. L. Eberling, W. J. Jagust, C. W. Christine, P. Starr, P. Larson, K. S. Bankiewicz, and M. J. Aminoff, "Results from a phase I safety trial of hAADC gene therapy for Parkinson disease," Neurology,70(21),1980- 1983(2008).
8. P. R. Johnson, B. C. Schnepp, M. J. Connell, D. Rohne, S. Robinson, G. R. Krivulka, C. I. Lord, R. Zinn, D. C. Montefiori, N. L. Letvin, and K. R. Clark, "Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques," J Virol,79(2),955-965(2005).
9. C. S. Manno, G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, M. Dake, R. Kaye, M. Razavi, A. Zajko, J. Zehnder, P. K. Rustagi, H. Nakai, A. Chew, D. Leonard, J. F. Wright, R. R. Lessard, J. M. Sommer, M. Tigges, D. Sabatino, A. Luk, H. Jiang, F. Mingozzi, L. Couto, H. C. Ertl, K. A. High, and M. A. Kay, "Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response," Nat Med,12(3),342-347(2006).
10. J. Lin, Y. Zhi, L. Mays, and J. M. Wilson, "Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice," J Virol,81(21),11840-11849(2007).
11. J. Lin, R. Calcedo, L. H. Vandenberghe, J. M. Figueredo, and J. M. Wilson, "Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines," Hum Gene Ther,19(7),663-669(2008).
12. M. Themis, S. N. Waddington, M. Schmidt, C. von Kalle, Y. Wang, F. Al-Allaf, L. G. Gregory, M. Nivsarkar, M. Themis, M. V. Holder, S. M. Buckley, N. Dighe, A. T. Ruthe, A. Mistry, B. Bigger, A. Rahim, T. H. Nguyen, D. Trono, A. J. Thrasher, and C. Coutelle, "Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice," Mol Ther,12(4),763-771(2005).
13. F. W. Van Ginkel, C. Liu, J. W. Simecka, J. Y. Dong, T. Greenway, R. A. Frizzell, H. Kiyono, J. R. McGhee, and D. W. Pascual, "Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase," Hum Gene Ther,6(7),895-903(1995).
14. R. D. McCoy, B. L. Davidson, B. J. Roessler, G. B. Huffnagle, S. L. Janich, T. J. Laing, and R. H. Simon, "Pulmonary inflammation induced by incomplete or inactivated adenoviral particles," Hum Gene Ther,6(12),1553-1560(1995).
15. D. Schaffert and E. Wagner, "Gene therapy progress and prospects: synthetic polymer-based systems," Gene Ther(2008).
16. Y. Zou, G. Zong, Y. H. Ling, and R. Perez-Soler, "Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer," Cancer Gene Ther,7(5),683-696(2000).
17. V. J. Dzau, M. J. Mann, R. Morishita, and Y. Kaneda, "Fusigenic viral liposome for gene therapy in cardiovascular diseases," Proc Natl Acad Sci U S A,93(21),11421-11425(1996).
18. T. McKay, M. Patel, R. J. Pickles, L. G. Johnson, and J. C. Olsen, "Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors," Gene Ther,13(8),715-724(2006).
19. Y. Kaneda, T. Nakajima, T. Nishikawa, S. Yamamoto, H. Ikegami, N. Suzuki, H. Nakamura, R. Morishita, and H. Kotani, "Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system," Mol Ther,6(2),219-226(2002).
20. K. Honma, F. Takeshita, and T. Ochiya, "[Application of atelocollagen-mediated siRNA delivery for RNAi therapies]," Yakugaku Zasshi,127(5),807-812(2007).
21. C. Dufes, I. F. Uchegbu, and A. G. Schatzlein, "Dendrimers in gene delivery," Adv Drug Deliv Rev,57(15),2177-2202(2005).
22. H. Eliyahu, Y. Barenholz, and A. J. Domb, "Polymers for DNA delivery," Molecules,10(1),34-64(2005).
23. K. Itaka, S. Ohba, K. Miyata, H. Kawaguchi, K. Nakamura, T. Takato, U. I. Chung, and K. Kataoka, "Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles," Mol Ther,15(9),1655-1662(2007).
24. D. Akagi, M. Oba, H. Koyama, N. Nishiyama, S. Fukushima, T. Miyata, H. Nagawa, and K. Kataoka, "Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation," Gene Ther,14(13),1029-1038(2007).
25. J. M. Hsieh, M. L. Ho, P. W. Wu, P. T. Chou, T. T. Tsai, and Y. Chi, "Iridium-complex modified CdSe/ZnS quantum dots; a conceptual design for bi-functionality toward imaging and photosensitization," Chem Commun (Camb)(6),615-617(2006).
26. E. B. Voura, J. K. Jaiswal, H. Mattoussi, and S. M. Simon, "Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy," Nat Med,10(9),993-998(2004).
27. B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou, and A. Libchaber, "In vivo imaging of quantum dots encapsulated in phospholipid micelles," Science,298(5599),1759-1762(2002).
28. M. Takeda, H. Tada, H. Higuchi, Y. Kobayashi, M. Kobayashi, Y. Sakurai, T. Ishida, and N. Ohuchi, "In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drugdelivery systems and tailor-made medicine," Breast Cancer,15(2),145-152(2008).
29. M. E. Akerman, W. C. Chan, P. Laakkonen, S. N. Bhatia, and E. Ruoslahti, "Nanocrystal targeting in vivo," Proc Natl Acad Sci U S A,99(20),12617-12621(2002).
30. S. Kim, Y. T. Lim, E. G. Soltesz, A. M. De Grand, J. Lee, A. Nakayama, J. A. Parker, T. Mihaljevic, R. G. Laurence, D. M. Dor, L. H. Cohn, M. G. Bawendi, and J. V. Frangioni, "Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping," Nat Biotechnol,22(1),93-97(2004).
31. A. Hoshino, Y. I. Kawamura, M. Yasuhara, N. Toyama-Sorimachi, K. Yamamoto, A. Matsukawa, S. A. Lira, and T. Dohi, "Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions," J Immunol,178(8),5296-5304(2007).
32. A. Hoshino, T. Nagao, T. Ito-Ihara, A. Ishida-Okawara, K. Uno, E. Muso, N. Nagi-Miura, N. Ohno, K. Tokunaka, S. Naoe, H. Hashimoto, M. Yasuhara, K. Yamamoto, and K. Suzuki, "Trafficking of QDconjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice," Microbiol Immunol,51(5),551-566(2007).
33. M. Ebbesen and T. G. Jensen, "Nanomedicine: techniques, potentials, and ethical implications," J Biomed Biotechnol,2006(5),51516(2006).
34. R. A. Freitas, Jr., "Nanotechnology, nanomedicine and nanosurgery," Int J Surg,3(4),243-246(2005).
35. S. D. Caruthers, S. A. Wickline, and G. M. Lanza, "Nanotechnological applications in medicine," Curr Opin Biotechnol,18(1),26-30(2007).
36. R. M. Navalakhe and T. D. Nandedkar, "Application of nanotechnology in biomedicine," Indian J Exp Biol,45(2),160-165(2007).
37. M. S. Arayne and N. Sultana, "Review: nanoparticles in drug delivery for the treatment of cancer," Pak J Pharm Sci,19(3),258-268(2006).
38. H. Lin and R. H. Datar, "Medical applications of nanotechnology," Natl Med J India,19(1),27-32(2006).
39. A. Hoshino, T. Ito-Ihara, A. Ishida-Okawara, E. Muso, K. Yamamoto, and K. Suzuki, "Detection of neutrophil MPO in patient with Rapidly Progressive Glumerulonephritis," Journal of Medical Technology,50(12),1409-1415(2006).
40. A. Hoshino, K. Fujioka, T. Oku, S. Nakamura, M. Suga, Y. Yamaguchi, K. Suzuki, M. Yasuhara, and K. Yamamoto, "Quantum dots targeted to the assigned organelle in living cells," Microbiol Immunol,48(12),985-994(2004) .
41. G. Bhakta, S. Mitra, and A. Maitra, "DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery," Biomaterials,26(14),2157-2163(2005).
42. D. J. Bharali, I. Klejbor, E. K. Stachowiak, P. Dutta, I. Roy, N. Kaur, E. J. Bergey, P. N. Prasad, and M. K. Stachowiak, "Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain," Proc Natl Acad Sci U S A,102(32),11539-11544(2005).
43. N. Jia, Q. Lian, H. Shen, C. Wang, X. Li, and Z. Yang, "Intracellular delivery of quantum dots tagged antisense oligodeoxynucleotides by functionalized multiwalled carbon nanotubes," Nano Lett,7(10),2976-2980(2007).
44. V. Biju, D. Muraleedharan, K. Nakayama, Y. Shinohara, T. Itoh, Y. Baba, and M. Ishikawa, "Quantum dotinsect neuropeptide conjugates for fluorescence imaging, transfection, and nucleus targeting of living cells," Langmuir,23(20),10254-10261(2007).
45. C. Srinivasan, J. Lee, F. Papadimitrakopoulos, L. K. Silbart, M. Zhao, and D. J. Burgess, "Labeling and intracellular tracking of functionally active plasmid DNA with semiconductor quantum dots," Mol Ther,14(2),192-201(2006).
46. A. Hoshino, K. Fujioka, T. Oku, M. Suga, Y. F. Sasaki, T. Ohta, M. Yasuhara, K. Suzuki, and K. Yamamoto, "Physicochemical Properties and Cellular Toxicity of Nanocrystal Quantum Dots Depend on Their Surface Modification," Nano Lett.,4(11),2163-2169(2004).
47. A. Hoshino, N. Manabe, K. Fujioka, S. Hanada, M. Yasuhara, A. Kondo, and K. Yamamoto, "GFP expression by intracellular gene delivery of GFP-coding fragments using nanocrystal quantum dots," Nanotechnology,19(49), 495102(2008).
48. K. Hanaki, A. Momo, T. Oku, A. Komoto, S. Maenosono, Y. Yamaguchi, and K. Yamamoto, "Semiconductor quantum dot/albumin complex is a long-life and highly photostable endosome marker," Biochem Biophys Res Commun,302(3),496-501(2003).
49. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira, "A Toll-like receptor recognizes bacterial DNA," Nature,408(6813),740-745(2000).
50. S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, and C. Reis e Sousa, "Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA," Science,303(5663),1529-1531(2004).
51. E. Latz, A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock, "TLR9 signals after translocating from the ER to CpG DNA in the lysosome," Nat Immunol,5(2),190-198(2004).